Life Sciences

Marlborough medical device manufacturer ReWalk Robotics has entered into two agreements to distribute product lines to the U.S. market from two companies in Florida and Israel.

Marlborough-based Web Industries Inc. announced Thursday it will hire 125 skilled equipment operators, engineering personnel, bio scientists, quality assurance, purchasing and inventory specialists over the next three months at its Holliston facility.

Marlborough medical device manufacturer ReWalk Robotics on Thursday reported 50% less revenue in the first quarter, compared to the same time period in 2019, the company announced on Thursday.

Marlborough pharmaceutical firm Sunovion said Thursday it has received federal approval for the first drug for Parkinson's disease which dissolves under the tongue.

ReWalk Robotics, the Marlborough medical device manufacturer, has revised its sponsored research agreement with Harvard University to focus increasingly now researching how the company’s wearable exosuits are comparable with telehealth services, the company announced on Tuesday.

Oxford Immunotec, based out of Marlborough and Oxford, United Kingdom, announced on Tuesday the release of its T-SPOT Discovery SARS-CoV-2 test kit, which the company said could help researchers further understand how immunity to the coronavirus works.

WuXi Biologics, a Chinese life sciences company slated to anchor a new biomanufacturing complex in Worcester, has closed on a deal with the property owner, the Worcester Business Development Corp.

WuXi Biologics, the biomanufacturing firm looking to build a $60-million facility on Belmont Street in Worcester, has made a down deposit on the project, further committing the company to the project.

Ashland biomanufacturing firm Boston Bioproducts will move to Milford following its purchase of a $5.65 million facility at 425 Fortune Blvd. in the town, the company confirmed on Friday.

Holliston-based Harvard Bioscience announced Thursday that Susan Steele has been appointed to the company’s Board of Directors as a Class III director in a move to appease an activist investor company planning to nominate their own board member candidates.